Pharmsynthez Stock

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS Other stock markets 08/07/2022			5-day change	1st Jan Change
4.505 ^RUB	+10.15%		-.--%	-

03/06	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Companyâ€™s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
LIFE Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	1.36B 107B 1.19B 1.11B 1.02B 1.91B 130B 1.94B 13.15B 5.15B 64.25B 5.09B 4.98B 222B	P/E 2021	-2.42x	P/E 2022	-6.53x
Enterprise Value	2.09B 165B 1.84B 1.71B 1.57B 2.95B 200B 3B 20.29B 7.94B 99.13B 7.85B 7.69B 343B	EV / Sales 2021	5.43x	EV / Sales 2022	5.51x
Free-Float	95.22%	Yield 2021 *	-	Yield 2022	-

03/06	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI
28/11	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
30/08/25	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/09/23	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023	CI
19/05/23	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
19/05/23	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	CI
08/11/22	Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation	CI
28/04/22	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
12/11/21	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021	CI
16/10/21	Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez	CI
14/04/21	Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure	MT
02/03/21	Public Joint-Stock Company Pharmsynthez Reports Earnings Results for the Full Year Ended December 31, 2018	CI

5 years	2.64		7
10 years	2.64		18.75

Manager	Title	Age	Since
Petr Vladimirovich Kruglyakov CEO	Chief Executive Officer	48	01/01/2014
Alexey Shafranov DFI	Director of Finance/CFO	47	-
Dmitriy Nikolayevich Poznyak CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dmitriy Genkin CHM	Chairman	57	01/01/2005
Indrek Kasela BRD	Director/Board Member	54	01/01/2007
Steve Gorelik BRD	Director/Board Member	47	01/01/2007

Pharmsynthez Stock

Stocks

LIFE

RU000A0JR514

Pharmaceuticals

Valuation: Pharmsynthez

Latest news : Pharmsynthez

Quotes and Performance

Course Extremes

Managers and Directors: Pharmsynthez

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHARMSYNTHEZ	+10.15%	-.--%	-.--%	-.--%	25.27M
ELI LILLY AND COMPANY	+0.27%	+5.09%	+60.20%	+168.89%	1,089B
JOHNSON & JOHNSON	+0.47%	+4.58%	+59.03%	+59.58%	643B
ABBVIE INC.	+1.30%	+4.83%	+38.87%	+77.52%	465B
ROCHE HOLDING AG	-0.99%	+9.54%	+40.31%	+34.55%	359B
NOVARTIS AG	-0.54%	+3.53%	+36.99%	+42.48%	303B
ASTRAZENECA PLC	+1.62%	+3.45%	+17.76%	+17.47%	267B
NOVO NORDISK A/S	+0.52%	+5.60%	-2.74%	-38.22%	226B
AMGEN INC.	+0.44%	+8.00%	+30.24%	+68.84%	212B
GILEAD SCIENCES, INC.	-0.81%	+2.77%	+17.27%	+75.93%	167B
Average	+1.17%	+5.58%	+29.79%	+50.71%	373.12B
Weighted average by Cap.	+0.20%	+5.14%	+43.06%	+82.22%

	2021	2022
Net sales	438M 34.52B 385M 358M 329M 618M 41.88B 628M 4.25B 1.66B 20.77B 1.65B 1.61B 71.75B	380M 29.9B 333M 310M 285M 535M 36.27B 544M 3.68B 1.44B 17.99B 1.43B 1.39B 62.15B
Net income	-698M -54.94B -612M -570M -524M -983M -66.64B -1B -6.76B -2.65B -33.05B -2.62B -2.56B -114B	-207M -16.34B -182M -170M -156M -292M -19.82B -297M -2.01B -787M -9.83B -779M -762M -33.97B
Net Debt	693M 54.57B 608M 566M 521M 976M 66.2B 993M 6.72B 2.63B 32.83B 2.6B 2.55B 113B	736M 57.98B 646M 602M 553M 1.04B 70.34B 1.06B 7.14B 2.79B 34.88B 2.76B 2.7B 121B